Inhibition of MCL-1 enhances Lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Prior studies demonstrated that resistance to the ERBB1/2 inhibitor Lapatinib in HCT116 cells was mediated by increased MCL-1 expression. We examined whether inhibition of BCL-2 family function could restore Lapatinib toxicity in Lapatinib adapted tumor cells and enhance Lapatinib toxicity in naive cells. The BCL-2 family antagonist Obatoclax (GX15-070), that inhibits BCL-2/BCL-X(L)/MCL-1 function, enhanced Lapatinib toxicity in parental HCT116 and Lapatinib adapted HCT116 cells. In breast cancer lines, regardless of elevated ERBB1/2 expression, GX15-070 enhanced Lapatinib toxicity within 3-12 h. The promotion of Lapatinib toxicity neither correlated with cleavage of caspase 3 nor was blocked by inhibition caspases; and was not associated with changes in the activities of ERK1/2, JNK1/2 or p38 MAPK but with reduced AKT, mTOR and S6K1 phosphorylation. The promotion of Lapatinib toxicity by GX15-070 correlated with increased cytosolic levels of apoptosis inducing factor (AIF) and expression of ATG8 (LC3), and the formation of large vesicles that intensely stained for a transfected LC3-GFP construct. Knock down of the autophagy regulatory proteins ATG5 or Beclin1 suppressed the induction of LC3-GFP vesicularization and significantly reduced cell killing, whereas knock down of MCL-1 and BCL-X(L) enhanced the induction of LC3-GFP vesicularization and significantly enhanced cell killing. Knockdown of Beclin1 and AIF abolished cell killing. Collectively, our data demonstrate that Obatoclax mediated inhibition of MCL-1 rapidly enhances Lapatinib toxicity in tumor cells via a toxic form of autophagy and via AIF release from the mitochondrion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E.-L., Mizushima, N., Ohsumi, Y., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci20039 · Cited by 2,311 · cited 2×
“, Beclin1, in breast cancer cells leads to increased cancer incidence; and activated oncogenes in general have been shown to inhibit autophagy and tumor suppressors to promote autophagy.(44) We noted that H-RAS V12, in protecting HCT116 cells from serum withdrawal + Lapatinib toxicity also suppressed increased levels…”
BackgroundBean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Schimmer, A. D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., Yee, K., Ravandi, F., Giles, F., Schuh, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0999 · Cited by 192 · cited 1×
“Based on published Phase I trial data, the sustainable free plasma concentrations of Gossypol and Obatoclax are ~600 nM and ~200 nM, respectively; the C max for Gossypol is ~3 μM and Gossypol has a very short half life in serum.(33,34) Obatoclax (50–100 nM) significantly enhanced the toxicity of serum starvation in wi…”
BackgroundUnleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185 · cited 1×
“promote the toxicity of other therapeutic agents.(23,24) The present studies determined: whether inhibition of BCL-2 family function could restore Lapatinib toxicity in Lapatinib adapted tumor cells and enhance Lapatinib toxicity in naive cells.”
Background
Cited by
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
“However, there are studies in which auto-phagy activation has an inverse role, contributing to tumor cell killing by a variety of agents (Martin et al. 2009; Hamed et al. 2010).”
Autophagy as a target for anticancer therapy
Janku, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 803
Regulation and Function of Autophagy during Cell Survival and Cell Death
Das, G., Shravage, B. V., & Baehrecke, E. H. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008813 · Cited by 408
Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy
Fulda, S., & Kögel, D. (2015) · Oncogene · doi:10.1038/onc.2014.458 · Cited by 307
Targeting autophagy during cancer therapy to improve clinical outcomes
Levy, J. M. M., & Thorburn, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.009 · Cited by 237
Basit, F., Cristofanon, S., & Fulda, S. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.45 · Cited by 211
“GX15-070 has previously been shown to initiate autophagy by disrupting the interaction between Beclin1 and antiapoptotic Bcl-2 proteins, such as Mcl-1.”
BackgroundInfluentialMCL‐1 is a stress sensor that regulates autophagy in a developmentally regulated manner
Germain, M., Nguyen, A. P., Le Grand, J. N., Arbour, N., Vanderluit, J. L., Park, D. S., Opferman, J. T., & Slack, R. S. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.327 · Cited by 159
Metadata
- Authors
- Pandya Martin, A., Mitchell, C., Rahmani, M., Nephew, K. P., Grant, S., & Dent, P.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2009-11-01
- Volume
- 8
- Issue
- 21
- Pages
- 2084-2096
- ISSN
- 1538-4047 (ISSN-L)
- OpenAlex
- W2040875703
- Cited by
- 98
- References
- 5
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.